BBOT to Participate in Upcoming December Investor Healthcare Conferences
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
BBOT to Participate in the Jefferies Global Healthcare Conference in London
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hypergly